CLINICAL STUDY ON AT-2266
1984 Volume 32 Issue Supplement3 Pages 457-463
Details
1984 Volume 32 Issue Supplement3 Pages 457-463
A new drug, AT-2266, was given orally to a total of 37 patients with infectious diseases (1 case with acute tonsillitis, 6 cases with acute pharyngitis, 20 cases with acute bronchitis and 10 cases with exacerbation of chronic bronchitis), and following results were obtained.
The daily dose of this drug ranged from 600 to 900 mg.
1) Clinical effectiveness:
The clinical response in acute tonsillitis was evaluated as good in 1 case. In acute pharyngitis is was evaluated as good in 3 cases and poor in 2. The clinical response in acute bronchitis was evaluated as good in 12 cases, air in 3 and poor in 5. In exacerbation of chronic bronchitis it was evaluated as excellent in 1 case, good in 6, fair in 2 and poor in 1.
The overall efficacy rate in 36 cases was 63.9%.
2) Bacteriological effectiveness: The 3 strains of S. pneumoniae, H. influenzae and β-Streptococccus was isolated from sputa and the mucous of pharynx in the patients with respiratory tract infection. All these strains excepting 1 strain of S. pneumoniae were eliminated by this drug.
3) Side effecst:
One adverse reaction due to this drug was observed.
In 2 cases, nausea was observed. However, this disappeared soon after ceasing the administration of the drug.
